Alexander von Rücker
About
In The Last Decade
Alexander von Rücker
18 papers receiving 432 citations
Peers
Comparison fields: 5 of 69
- Molecular Biology 193
- Oncology 134
- Immunology 133
- Pulmonary and Respiratory Medicine 94
- Pathology and Forensic Medicine 66
Countries citing papers authored by Alexander von Rücker
This map shows the geographic impact of Alexander von Rücker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander von Rücker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander von Rücker more than expected).
Fields of papers citing papers by Alexander von Rücker
This network shows the impact of papers produced by Alexander von Rücker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander von Rücker. The network helps show where Alexander von Rücker may publish in the future.
Co-authorship network of co-authors of Alexander von Rücker
This figure shows the co-authorship network connecting the top 25 collaborators of Alexander von Rücker. A scholar is included among the top collaborators of Alexander von Rücker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander von Rücker. Alexander von Rücker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 16 | |
| 2 | 2 | |
| 3 | 3 | |
| 4 | 1 | |
| 5 | 40 | |
| 6 | 2 | |
| 7 | 1 | |
| 8 | 101 | |
| 9 | Indirubin-3'-monoxime, a CDK inhibitor induces growth inhibition and apoptosis-independent up-regulation of survivin in transitional cell cancer. | 36 |
| 10 | 66 | |
| 11 | GSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer: is there a correlation with clinical stage, Gleason grade, PSA value or age? | 27 |
| 12 | 1 | |
| 13 | 2 | |
| 14 | 13 | |
| 15 | 26 | |
| 16 | 95 | |
| 17 | 8 | |
| 18 | 1 | |
| 19 | 12 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.